Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies
Authors:
Open Access
- 14 July 2017
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 828
Abstract
Tumor-associated macrophages (TAMs) play a central role in tumor progression, metastasis and recurrence after treatment. Macrophage plasticity and diversity allow their classification along a M1 – M2 polarization axis. Tumor–associated macrophages usually display a M2-like phenotype, associated with pro-tumoral features whereas M1 macrophages exert anti-tumor functions. Targeting the reprogramming of TAMs towards M1-like macrophages would thus be an efficient way to promote tumor regression. This can be achieved through therapies including chemotherapy, immunotherapy and radiotherapy. In this review, we first describe how chemo- and immuno-therapies can target TAMs and secondly we detail how radiotherapy modifies macrophage phenotype and present the molecular pathways that may be involved. The identification of irradiation dose inducing macrophage reprogramming and of the underlying mechanisms could lead to the design of novel therapeutic strategies and improve synergy in combined treatments.Keywords
Funding Information
- Fonds De La Recherche Scientifique - FNRS
This publication has 157 references indexed in Scilit:
- ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophagesCell Research, 2013
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The multikinase inhibitor Sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE2 in murine macrophagesInternational Immunopharmacology, 2010
- Alternative Activation of Macrophages: Mechanism and FunctionsImmunity, 2010
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptorsNature Immunology, 2010
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasisCytokine & Growth Factor Reviews, 2010
- Direct Interaction between Nrf2 and p21Cip1/WAF1 Upregulates the Nrf2-Mediated Antioxidant ResponseMolecular Cell, 2009
- TLR9 as a key receptor for the recognition of DNA☆Advanced Drug Delivery Reviews, 2008
- Shared Principles in NF-κB SignalingCell, 2008